RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src

Overexpression of EGFR is commonly seen in gastric cancer (GC). However, patients with GC show resistance to anti-EGFR treatments. RAS mutations are rare in GC and cannot explain de novo resistance to EGFR treatments. Therefore, it is particularly important to explore the mechanisms of resistance to...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Onco Targets Ther
Hoofdauteurs: Zhang, Xiaomeng, Song, Yongxi, Song, Na, Zhang, Ye, Zhang, Lingyun, Wang, Yan, Wang, Zhenning, Qu, Xiujuan, Liu, Yunpeng
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove Medical Press 2017
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5229171/
https://ncbi.nlm.nih.gov/pubmed/28123301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S110918
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items